Martin MacKay, EVP & Global Head of R&D at ALEXION PHARMACEUTICALS INC (ALXN), sold 43,500 shares at $197.24 ($8.5M) on 2015-08-03, disclosed to the SEC on 2015-08-05.
Open-market sale of $8.5M ALXN by EVP & Global Head of R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $195.19 | 8,882 | $1.7M | 20.3% |
| 2 | $196.48 | 17,518 | $3.4M | 40.3% |
| 3 | $197.24 | 17,100 | $3.4M | 39.5% |
| Total | $196.52 avg | 43,500 | $8.5M | 100% |
| Filing → |
| ALXN | SELL | 2017-02-10 | $28K | — | Filing → |
| ALXN | SELL | 2017-02-08 | $684K | — | Filing → |
| ALXN | SELL | 2016-05-18 | $1.1M | — | Filing → |